FY2024 Earnings Estimate for Hologic, Inc. (NASDAQ:HOLX) Issued By William Blair

Hologic, Inc. (NASDAQ:HOLX) – Investment analysts at William Blair lifted their FY2024 earnings per share estimates for Hologic in a report released on Friday, May 3rd. William Blair analyst A. Brackmann now anticipates that the medical equipment provider will earn $4.07 per share for the year, up from their prior estimate of $3.97. William Blair has a “Outperform” rating on the stock. The consensus estimate for Hologic’s current full-year earnings is $4.08 per share. William Blair also issued estimates for Hologic’s Q4 2024 earnings at $1.03 EPS, Q1 2025 earnings at $1.06 EPS, Q2 2025 earnings at $1.08 EPS, Q3 2025 earnings at $1.13 EPS, Q4 2025 earnings at $1.18 EPS and FY2025 earnings at $4.45 EPS.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts’ consensus estimates of $0.98 by $0.05. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1 billion. Hologic had a net margin of 11.78% and a return on equity of 18.91%. The business’s revenue for the quarter was down .8% on a year-over-year basis. During the same quarter last year, the business earned $1.06 earnings per share.

A number of other analysts have also recently issued reports on the company. Raymond James boosted their price objective on Hologic from $85.00 to $88.00 and gave the company an “outperform” rating in a research report on Friday, February 2nd. Citigroup raised shares of Hologic from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $80.00 to $95.00 in a report on Wednesday, April 3rd. UBS Group boosted their price objective on Hologic from $78.00 to $79.00 and gave the stock a “neutral” rating in a report on Friday, February 2nd. Needham & Company LLC reissued a “buy” rating and issued a $90.00 target price on shares of Hologic in a research note on Friday. Finally, Evercore ISI lifted their target price on Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a report on Thursday, April 4th. Five research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $84.56.

Hologic Stock Performance

Shares of HOLX stock opened at $75.93 on Monday. The company has a current ratio of 3.97, a quick ratio of 3.29 and a debt-to-equity ratio of 0.52. Hologic has a 1-year low of $64.02 and a 1-year high of $86.74. The stock’s fifty day simple moving average is $76.13 and its 200-day simple moving average is $73.09. The company has a market capitalization of $17.82 billion, a price-to-earnings ratio of 39.05, a P/E/G ratio of 2.55 and a beta of 1.01.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Empowered Funds LLC acquired a new stake in shares of Hologic during the 1st quarter valued at $234,000. Envestnet Portfolio Solutions Inc. increased its holdings in Hologic by 36.0% during the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 16,585 shares of the medical equipment provider’s stock worth $1,293,000 after purchasing an additional 4,392 shares in the last quarter. Empirical Finance LLC grew its position in Hologic by 3.2% in the 1st quarter. Empirical Finance LLC now owns 9,103 shares of the medical equipment provider’s stock worth $710,000 after purchasing an additional 283 shares in the last quarter. SPC Financial Inc. purchased a new stake in shares of Hologic during the 1st quarter valued at $1,005,000. Finally, Mediolanum International Funds Ltd bought a new position in shares of Hologic during the 1st quarter valued at approximately $1,793,000. Institutional investors own 94.73% of the company’s stock.

Insider Activity

In other Hologic news, Director Scott T. Garrett sold 16,441 shares of the firm’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the completion of the sale, the director now owns 48,611 shares of the company’s stock, valued at approximately $3,670,130.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Charles J. Dockendorff sold 1,465 shares of the stock in a transaction on Friday, March 8th. The stock was sold at an average price of $76.21, for a total transaction of $111,647.65. Following the sale, the director now directly owns 1,572 shares of the company’s stock, valued at approximately $119,802.12. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Scott T. Garrett sold 16,441 shares of the company’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the sale, the director now directly owns 48,611 shares of the company’s stock, valued at approximately $3,670,130.50. The disclosure for this sale can be found here. 1.75% of the stock is currently owned by insiders.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.